These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21160478)

  • 21. Case of Severe Hypertension and Nephrotic Range Proteinuria.
    Bursztyn M; Touyz RM; Laffer CL; Carey RM; Dominiczak AF
    Hypertension; 2018 Jun; 71(6):956-961. PubMed ID: 29610267
    [No Abstract]   [Full Text] [Related]  

  • 22. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrotic-range proteinuria in a patient with high renin hypertension: effect of treatment with an ACE-inhibitor.
    Docci D; Moscatelli G; Capponcini C; Baldrati L; Feletti C
    Am J Nephrol; 1992; 12(5):387-9. PubMed ID: 1489013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eplerenone's role in the management of complex cardiovascular disorders.
    Stewart Coats AJ; Shewan L
    Int J Cardiol; 2015 Dec; 200():1-2. PubMed ID: 26116081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of captopril in nephrotic-range proteinuria due to renovascular hypertension.
    Martinez Vea A; García Ruiz C; Carrera M; Oliver JA; Richart C
    Nephron; 1987; 45(2):162-3. PubMed ID: 3550500
    [No Abstract]   [Full Text] [Related]  

  • 27. Does eplerenone have a future in the management of hypertension in Europe?
    Gosse P; Macfadyen RJ
    J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301
    [No Abstract]   [Full Text] [Related]  

  • 28. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antihypertensive agents used as first line agents: beta-blockers under pressure].
    Burnier M; Pechère A; Waeber B
    Rev Med Suisse; 2006 Sep; 2(78):2019-20. PubMed ID: 17019836
    [No Abstract]   [Full Text] [Related]  

  • 34. Eplerenone for gitelman syndrome in pregnancy.
    Morton A; Panitz B; Bush A
    Nephrology (Carlton); 2011 Mar; 16(3):349. PubMed ID: 21342329
    [No Abstract]   [Full Text] [Related]  

  • 35. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
    Zhou X; Ono H; Ono Y; Frohlich ED
    Am J Nephrol; 2004; 24(2):242-9. PubMed ID: 15031627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
    Takata Y; Asano K; Yamashina A
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():336-41. PubMed ID: 15813091
    [No Abstract]   [Full Text] [Related]  

  • 37. Aldosterone antagonism and arterial stiffness.
    Safar ME; Avolio A
    Hypertension; 2004 Feb; 43(2):e3; author reply e3. PubMed ID: 14756124
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Takeda Y
    Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.